ZyVersa Therapeutics Announces Publication Of Article In Peer-reviewed Journal Showing Inhibiting NLRP3 Inflammasomes Can Attenuate Kidney Damage And Dysfunction Associated With PM2.5 Pollutant
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics has published an article in a peer-reviewed journal demonstrating that inhibiting NLRP3 inflammasomes can reduce kidney damage and dysfunction associated with PM2.5 pollutant. The company's stock symbol is ZVSA.
November 06, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ZyVersa Therapeutics' research on NLRP3 inflammasomes could potentially lead to new treatments for kidney damage, which may positively impact the company's stock.
The publication of this research in a peer-reviewed journal adds credibility to ZyVersa's work and could potentially lead to new treatments for kidney damage. This could increase the company's value and positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100